

In vivo application of CRISPR/Cas9-based technology

Fumiyuki Hatanaka, Ph.D
畠中 史幸 先生

Altos Labs Inc. San Diego Institute of Science,
Senior Scientist

Sep 26, 2022 (Mon) 16:00~17:30

神戸大学大学院医学研究科 研究棟B棟1階 第1講堂


Zoom meeting:

<https://kobe-u-ac->

[jp.zoom.us/j/81879146089?pwd=dEJRN1BOOTFPMU1zOXgydVJ0Ymlkdz09](https://kobe-u-ac-jp.zoom.us/j/81879146089?pwd=dEJRN1BOOTFPMU1zOXgydVJ0Ymlkdz09)

Meeting ID: 818 7914 6089

Passcode: 393771



Recent development of genome-editing technology has accelerated the pace of biological and biomedical research, especially the discovery of revolutionized technology CRISPR-Cas9 system from native immunity of bacterial defense. Taking the advantage and feasibility of this methodology, our group has particular interest in its applications in the manner of targeting therapeutics to treat human diseases. In this talk, I'd like to share our CRISPR/Cas9-based technology especially for *in vivo* applications.

<Related publication>

Liao and Hatanaka et al.,

In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Cell, 171(7):1495-1507, 2017

Kobe University Center for Medical Transformation
(Contact : Division of Physiology, 078-382-5385)